Burden of disease: Psoriasis and psoriatic arthritis

American Journal of Clinical Dermatology

Volumn 14, Issue 5, 2013, Pages 377-388

  Boehncke, Wolf Henning ^a   Menter, Alan ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APREMILAST; BRIAKINUMAB; BRODALUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; IXEKIZUMAB; JANUS KINASE 3; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV; PLACEBO; SECUKINUMAB; STEROID; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ADULT ONSET STILL DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMORBIDITY; DERMATOLOGIST; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING TEST; TH17 CELL; TREATMENT RESPONSE;

ARTHRITIS, PSORIATIC; COST OF ILLNESS; EMPLOYMENT; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; JANUS KINASE 3; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; QUALITY OF LIFE;

EID: 84885129470     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0032-x     Document Type: Review

References (93)

1. Prey S, Paul C, Bronsard V, et al. Assessment of the risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl. 2):31-5.
2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64.
3. Lloyd P, Ryan C, Menter A. Psoriatic arthritis: an update. Arthritis. 2012;2012:176298.
4. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002;82:108-13.
5. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040-7.
6. Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736-40
7. Lynde CW, Poulin Y, Guenther L, Jackson C. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg. 2009;13:235-52.
8. Laws P, Barton A, Warren RB. Psoriatic arthritis-what the dermatologist needs to know. J Eur Acad Dermatol Venereol. 2010;24:1270-7.
9. Yamamoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21:660-6.
10. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704-8.
11. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151-8.
12. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(Suppl. 11):S64-85.
13. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548-54.
14. Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology. 2012;51:571-6.
15. McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63:162-9.
16. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772-80.
17. Poole CD, Lebmeier M, Ara R, et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology. 2010;49:1949-56.
18. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002;8(Suppl. 21):S664-81.
19. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. Pharm Ther. 2010;35:680-9.
20. Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157-63.
21. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147-57.
22. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67:76-85.
23. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2012;72:211-6.
24. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care. 2011;63:1729-35.
25. Eder L, Jayakar J, Shanmugarajah S, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2012 (Epub ahead of print).
26. Boehncke WH, Boehncke S, Tobin A-M, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-7.
27. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14:343-8.
28. Boehncke WH. Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:441-4.
29. Kourosh AS, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett. 2008;13:1-5.
30. Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology. 2010;49:1399-405.
31. Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26:644-50.
32. Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl. 2012;89:4-6.
33. Boehncke WH, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303:381-8.
34. Boehncke WH, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25:1187-93.
35. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-50.
36. Di Minno MN, Iervolino S, Peluso R, on behalf of the CaRRDs study group, et al. Carotid intima-media thickness in psoriatic arthritis. Differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31:705-12.
37. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40-55.
38. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl. 1):i77-84.
39. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300-3.
40. Wittkowski KM, Leonardi C, Gottlieb A, et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One. 2011;6:e20279.
41. Taylor W, Gladman D, Helliwell P, CASPAR Study Group, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73.
42. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology. 2003;42:778-83.
43. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiologic damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis. 2007;66:370-6.
44. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med. 1987;62:127-41.
45. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30:245-50.
46. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology. 2003;42:1460-8.
47. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50.
48. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1-70.
49. Papp K, Gulliver W, Lynde C, Canadian Psoriasis Guidelines Committee, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15:210-9.
50. Ritchlin CT, Kavanaugh A, Gladman DD, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94.
51. Gossec L, Smolen JS, Gaujoux-Viala C, European League Against Rheumatism, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12.
52. Augustin M, Glaeske G, Schäfer I, et al. Processes of psoriasis health care in Germany: long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges. 2012;10:648-55.
53. Association of American Medical Colleges. 2008 physician specialty data. Center for Workforce Studies [online]. https://www.aamc.org/download/47352/data/ specialtydata.pdf. (Accessed 24 Sep 2012).
54. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease. Ann Rheum Dis. 2011;70:2152-4.
55. Iervolino S, Di Minno MN, Peluso R, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol. 2012;39:568-73.
56. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomized 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823-6.
57. Taylor SL, Petrie M, O'Rourke KS, Feldman SR. Rheumatologists' recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients' joint symptoms. J Dermatol Treat. 2009;20:350-3.
58. Dominguez P, Husni ME, Garg A, Quershi AA. Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:548-50.
59. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68:497-501.
60. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
61. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038-43.
62. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology. 2011;50:518-31.
63. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2012;273:197-204.
64. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186:1495-502.
65. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490-500.
66. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207-11.
67. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092-102.
68. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307-17.
69. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419-29.
70. van Baarsen LG, Lebre MC, van der Coelen D, et al. Expression levels of IL-17A, IL-17F and their receptors in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: a target validation study [abstract]. Ann Rheum Dis. 2011;70(Suppl. 3):536.
71. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum. 2012;64:99-109.
72. Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6:R120-8.
73. Adamopoulos IE, Chao CC, Geissler R, et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther. 2010;12:R29.
74. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535-45.
75. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
76. Mease PJ, Gladman DD, Ritchlin CT, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-89.
77. Antoni C, Krueger GG, de Vlam K, IMPACT 2 Trial Investigators, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7.
78. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study [abstract]. Ann Rheum Dis. 2012;71 Suppl. 3:107 (Abstract OP0158).
79. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412-21.
80. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-9.
81. Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med. 2012;366:1181-9.
82. McInnes I, Sieper J, Braun J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial [abstract]. Arthritis Rheum. 2011;63(10 Suppl.):S306.
83. Marder W, Khalatbari S, Myles JD, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1550-5.
84. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864-71.
85. Bigby M. The use of anti-interleukin-12/23 agents and major adverse cardiovascular events. Arch Dermatol. 2012;148:753-4.
86. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27:622-7.
87. Reich K, Papp KA, Griffiths CEM, PHOENIX 1, PHOENIX 2, and ACCEPT Investigators, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11:300-12.
88. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234-43.
89. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183:2183-92.
90. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842-55.
91. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668-77.
92. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738-46.
93. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156-67.